Iovance Biotherapeutics, Inc. (IOVA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 6.03B USD. 52-week range 1.76 to 15.30 USD. Data as of 2026-10-09.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an ...